NEW YORK (GenomeWeb News) – Canadian diagnostic test developer Miraculins said today that it has partnered with Inverness Medical Innovations to commercialize Miraculins' suite of biomarkers for preeclampsia.

Under the collaborative research and option agreement, Inverness, through its Biosite division, will develop tests for Miraculins' panel of 35 biomarkers involved in placenta development and the occurrence of preeclampsia, a potentially fatal pregnancy complication.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.